The Journal of Intellectual Property Law and Practice (vol. 7, issue 7) has published an article by partner Darren Smyth about a case in the UK Patents Court about AstraZeneca’s patent for its drug quetiapine, marketed as Seroquel.
AstraZeneca's European patent EP 0907364 relating to a sustained release formulation of the antipsychotic drug quetiapine was held invalid in the UK, this being the opposite outcome to parallel litigation before the District Court of the Hague.
To read the JIPLP article in full, click here.